Mycobacterium mucogenicum: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 17: | Line 17: | ||
==Overview== | ==Overview== | ||
'''''Mycobacterium mucogenicum''''' | '''''Mycobacterium mucogenicum''''' | ||
[[Etymology]]: mucogenicum, from the organism's highly [[mucoid]] appearance. | [[Etymology]]: mucogenicum, from the organism's highly [[mucoid]] appearance. | ||
| Line 53: | Line 53: | ||
[[Category:Gram positive bacteria]] | [[Category:Gram positive bacteria]] | ||
[[Category:Infectious Disease Project]] | [[Category:Infectious Disease Project]] | ||
Latest revision as of 15:55, 10 August 2015
| Mycobacterium mucogenicum | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Mycobacterium mucogenicum Springer et al. 1995, ATCC 49650 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mycobacterium mucogenicum Etymology: mucogenicum, from the organism's highly mucoid appearance.
Description
Gram-positive, nonmotile, curved and acid-fast rods.
Colony characteristics
- Highly mucoid behavior of most strains on solid agar. Smooth and off-white on Middlebrook 7H10 agar
Physiology
- Rapid growth on Middlebrook 7H10 at 28°C to 37°C, but not at 42°C, within 2 - 4 days.
- Susceptible to amikacin, imipenem, cefoxitin, clarithromycin and ciprofloxacin.
- Resistant to isoniazid and rifampin.
Pathogenesis
- Posttraumatic skin infections,
- catheter sepsis and respiratory isolates without clinical significance except in immunocompromised hosts.
- Biosafety level 2
Type Strain
- First isolated in 1976 during an outbreak of peritonitis associated with automated peritoneal dialysis machines in the north-western United States.
- Strain ATCC 49650 = CCUG 47451 = CIP 105223 = DSM 44625 = JCM 13575.
Treatment
Antimicrobial regimen
- In vitro susceptible agents: Aminoglycosides, Cefoxitin, Clarithromycin, Minocycline, Doxycycline, Quinolones, Trimethoprim/sulfamethoxazole, and Imipenem
References
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.
- Springer et al. 1995. Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int. J. Syst. Bacteriol., 45, 262-267.